PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Hyundai Bioscience is broadening its nicotinamide-based broad-spectrum antiviral platform 'Xafty' into dengue fever and prostate cancer indications, while its revenue base remains thin and losses continue to widen.
Hyundai Bioscience is running a global Phase 2/3 dengue trial for Xafty with Vietnam's National Hospital of Tropical Diseases, and the company disclosed on August 27 that the trial was proceeding on schedule.
The first patient dosing for the Phase 1 trial of 'Penetrium' (CP-PCA07), combined with enzalutamide for castration-resistant prostate cancer patients, began on August 14, 2026.
A capital increase of KRW 85.8 billion completed in 2025 boosted total equity and lowered the debt ratio from 71.7% to 18.1%.
Net loss attributable to owners in Q2 2026 reached KRW 11.56 billion, more than double the operating loss of KRW 5.54 billion for the same quarter.
The underlying patents for core pipeline assets are held by unlisted major shareholder C&Pharm, with Hyundai Bioscience operating under an exclusive license arrangement.
Hyundai Bioscience is a KOSDAQ-listed biotech developing new drugs based on drug delivery system (DDS) technology.
Its core pipeline is the broad-spectrum antiviral 'Xafty' (CP-COV03), a repurposed niclosamide formulation that began as a COVID-19 treatment and is now being expanded through a basket-trial strategy into dengue fever, Zika, influenza and other similar viral diseases.
The trial was designed to go beyond Part 1, which evaluates efficacy in dengue patients, into Part 2, which expands the indication to Zika, influenza and other similar flavivirus-family diseases.
To this end, the company is conducting a global Phase 2/3 dengue trial for Xafty jointly with Vietnam's National Hospital of Tropical Diseases (NHTD) and others; following a Site Initiation Visit in March 2026 and first patient enrollment and dosing in early April, the company disclosed on August 27 that the dengue trial in Vietnam was proceeding as planned.
In oncology, the company is developing an oral niclosamide-based metabolic anticancer drug targeting p53-mutant cancer cells, alongside a Phase 1 trial of 'Penetrium' (CP-PCA07) combined with enzalutamide for castration-resistant prostate cancer patients.
The intellectual property related to the formulation and manufacturing patents for this treatment is held by C&Pharm, and the company has been granted an exclusive license to the related patent-pending technology by C&Pharm.
Beyond its drug pipeline, the company also generates some revenue from cosmetics-related operations, though this remains a small portion of total sales.
Hyundai Bioscience has also formed a strategic partnership with the Drugs for Neglected Diseases initiative (DNDi), an international nonprofit organization, expanding cooperation with global health bodies.
The company stated it is also pursuing a Phase 2 basket trial in the United States targeting upper respiratory viral infections (URVI) using the same drug delivery technology.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩300M | -₩4.8B | −1447.4% |
| 2025Q3 | ₩600M | -₩4.6B | −835.3% |
| 2025Q4 | ₩1.9B | -₩4.4B | −230.9% |
| 2026Q1 | ₩300M | -₩4.7B | −1436.9% |
| 2026Q2 | ₩500M | -₩5.5B | −1063.7% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩7.9B | -₩26.4B | -₩15.8B | −335.7% | −27.1% | 15.6% |
| 2023 | ₩9.5B | -₩9.8B | -₩14.5B | −103.2% | −32.0% | 16.6% |
| 2024 | ₩15.1B | ₩800M | -₩6.9B | 5.3% | −17.6% | 71.7% |
| 2025 | ₩3.5B | -₩18.2B | -₩22.1B | −516.3% | −20.0% | 18.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
Annual revenue in 2025 was KRW 3.52 billion, sharply down from KRW 15.05 billion in 2024. Operating profit swung from a gain of KRW 0.79 billion in 2024 to a loss of KRW 18.16 billion in 2025, while net loss attributable to owners widened from KRW 6.93 billion to KRW 22.13 billion.
The company also posted operating losses of KRW 9.79 billion in 2023 and KRW 26.35 billion in 2022, reflecting a multi-year pattern of losses.
Operating cash flow likewise reversed from an inflow of KRW 2.26 billion in 2024 to an outflow of KRW 17.05 billion in 2025, indicating weakened cash generation from core operations.
On a quarterly basis, revenue briefly rebounded from KRW 0.33 billion in Q2 2025 to KRW 1.92 billion in Q4 2025, before falling back to KRW 0.32 billion in Q1 2026 and KRW 0.52 billion in Q2 2026.
Quarterly operating losses widened from KRW 4.82 billion in Q2 2025 to KRW 5.54 billion in Q2 2026, reflecting continued R&D spending pressure.
Notably, the net loss attributable to owners in Q2 2026 reached KRW 11.56 billion, more than double the operating loss for the same quarter, suggesting non-operating factors played a significant role in widening the loss.
The combined net loss attributable to owners over the trailing four quarters (Q3 2025 through Q2 2026) reached KRW 28.61 billion, indicating losses have grown on an annualized basis as well.
Total equity rose sharply from KRW 39.44 billion in 2024 to KRW 110.73 billion in 2025, a change attributable to the KRW 85.8 billion capital increase completed in February 2025, while the debt ratio over the same period fell from 71.7% to 18.1%.
Dengue fever infects roughly 400 million people annually across more than 120 countries, yet it remains classified as a disease without an approved treatment.
Dengue fever is one of the representative infectious diseases that repeatedly causes large-scale outbreaks in tropical and subtropical regions including Southeast Asia, but it is classified as a disease lacking an approved treatment.
Reports citing health experts, including the International Vaccine Institute (IVI), have analyzed that if a dengue treatment is commercialized, its impact could reach an annual market size of roughly KRW 5 trillion (about USD 3.8 billion).
Forecasts also suggest the market could grow further as climate change pushes outbreak regions further north. On the competitive front, reports indicate that global competitors such as Japan's Shionogi and the United States' MSD are also exploring dengue treatment candidates.
In prostate cancer treatment, limited treatment options for castration-resistant patients who have developed resistance to second-line hormonal therapies such as enzalutamide are cited as the background for developing new combination therapies.
However, the company has disclosed as an investment caution that the probability of a clinical drug ultimately being approved as a medicine is statistically only around 10%.
Across the broader KOSDAQ biotech sector, clinical-stage companies often exhibit similar capital-raising and cash-flow structures, with pipeline value tending to hinge heavily on clinical data outcomes.
The Vietnam dengue trial initially aimed to complete the study within the year and, once efficacy is confirmed, apply for an Emergency Use Authorization (EUA) locally. The company disclosed on August 27 that the Vietnam trial was proceeding as planned.
In prostate cancer, first patient dosing in the Phase 1 trial of CP-PCA07 (Penetrium) occurred on August 14, 2026, and on September 4 the company applied to the Ministry of Food and Drug Safety for approval of a Phase 1 trial plan amendment for the prostate cancer drug candidate 'CP-PCA07', reflecting PCWG3 guidelines.
The amendment adds an AR-V7 gene mutation test at the patient screening stage, which excludes patients with 'genuine' resistance where the receptor itself is altered and the drug has no effect. The trial period is expected to run for approximately 24 months from the approval date.
The company also stated plans to solidify its position as a global standard treatment through a Phase 2 basket trial targeting upper respiratory viral infections (URVI) in the United States using the same platform.
However, the company itself has cautioned in investment advisories that the trial period may change depending on factors such as the pace of subject enrollment.
Over the past several years, the company has generated minimal revenue-based income while recording repeated large R&D expenses and non-operating losses, resulting in a persistent loss structure.
The large capital increase in 2025 boosted total equity and lowered the debt ratio, outwardly expanding the company's financial buffer. However, because cash continues to flow out from operating activities, the need for additional fundraising could resurface if clinical trials are prolonged.
Shares tend to trade at a notable premium relative to net asset value, suggesting that expectations about pipeline success, rather than current earnings, weigh more heavily on how the market values the company.
No dividend is currently paid, meaning capital gains or losses from share price movement are effectively the only return channel for investors. Under this structure, market interpretation of valuation can diverge sharply each time clinical results or new fundraising disclosures are announced.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
Simultaneous progress on the Xafty-based dengue/Zika/influenza basket trial and the prostate cancer combination therapy trial reduces reliance on any single pipeline asset. Dengue fever remains a disease without an approved treatment, positioning the company to potentially address an unmet market if successful. The parallel URVI basket trial in the United States adds geographic and indication diversification.
The KRW 85.8 billion capital increase completed in 2025 sharply boosted total equity versus the prior year and lowered the debt ratio from 71.7% to 18.1%. This eases near-term funding pressure typical of biotech companies that continuously incur clinical trial costs. The subscription was also reported to have drawn strong demand at the time.
Reports indicate that Vietnamese health ministry vice-minister-level officials attended the dengue trial launch event, reflecting local authorities' interest and support. The company has also pursued cooperation with international nonprofits such as DNDi through strategic partnerships. Such networks could provide a favorable environment for trial progress and future approval processes.
2025 revenue was only around KRW 3.5 billion, providing almost no core business income to offset an annual operating loss exceeding KRW 18 billion. Operating cash flow also turned negative at roughly KRW -17 billion in 2025, indicating weakened cash generation from core operations. Unless the revenue base recovers, reliance on external fundraising could continue.
Net loss attributable to owners in Q2 2026 exceeded KRW 11.5 billion, showing a pattern of widening quarterly losses. The trailing four-quarter combined net loss also surpassed KRW 28.6 billion, indicating losses are growing on an annualized basis.
The recurring pattern of net loss exceeding operating loss by a wide margin warrants scrutiny of non-operating volatility.
The underlying patents for core pipeline assets Xafty and CP-PCA07 are held by unlisted major shareholder C&Pharm, with Hyundai Bioscience operating under an exclusive license structure. This arrangement carries potential exposure to business stability if license terms or related-party transactions change. Investors need to continuously monitor related transaction disclosures.
The company discloses as an investment caution that the statistical probability of a clinical drug ultimately being approved as a medicine is around 10%. Major pipelines including the prostate cancer and dengue programs remain in early-to-mid stage trials, meaning prior investment could become sunk cost if trials fail. Although multiple pipelines are underway, the success of each trial should be assessed independently.
The company's operating activities continue to consume cash, with 2025 operating cash flow at roughly KRW -17 billion. If trials are prolonged or costs rise further, additional external funding such as rights offerings or convertible bond issuance may again become necessary. This also raises the possibility of dilution for existing shareholders.
Core underlying patents for pipeline assets such as Xafty and CP-PCA07 are held by unlisted major shareholder C&Pharm, with Hyundai Bioscience operating under an exclusive license.
Under this structure, changes to license terms or related-party transaction issues could affect business operations and investor confidence. Transparency of related transactions through disclosures is an important factor to verify.
Expected filing of the Q3 2026 (July-September) quarterly report, allowing a check on revenue, operating loss, and cash and cash equivalents trends.
Potential disclosure of Part 1 efficacy data from the Vietnam dengue trial and whether a local Emergency Use Authorization application is filed, in line with the company's original goal of completing the trial within the year.
A period to monitor the pace of patient enrollment and any interim data disclosures, such as PSA changes, in the CP-PCA07 (Penetrium) prostate cancer Phase 1 trial.
A point to check progress on the U.S. URVI basket Phase 2 trial and the outcome of discussions with regulatory authorities.
Hyundai Bioscience is a clinical-stage biotech expanding its niclosamide-based broad-spectrum antiviral platform into multiple indications including dengue fever and prostate cancer.
The KRW 85.8 billion capital increase in 2025 strengthened equity and lowered the debt ratio, but the revenue base remains thin and operating cash flow continues to be negative. Quarterly results show losses widening rather than narrowing, with Q2 2026 net loss attributable to owners exceeding KRW 11.5 billion.
While pipeline diversification is underway through the parallel Vietnam dengue trial and prostate cancer combination therapy trial, both remain at early-to-mid clinical stages, and the company itself discloses that the probability of final approval is low.
The governance structure, in which core patents are held by unlisted major shareholder C&Pharm under an exclusive license arrangement, remains a factor warranting ongoing attention.
Future clinical data releases and any additional fundraising will likely serve as key inflection points for how the company's value is assessed.
Report written 2026-10-03 · Data as of 2026-10-02
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.